PROSHARES TRUST (ZBIO) EBIAT: 2023-2025
Historic EBIAT for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.
- Zenas BioPharma's EBIAT fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.9 million, marking a year-over-year decrease of 47.24%. This contributed to the annual value of -$157.0 million for FY2024, which is 322.91% down from last year.
- As of Q3 2025, Zenas BioPharma's EBIAT stood at -$51.5 million, which was up 1.38% from -$52.2 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's EBIAT registered a high of $35.6 million during Q3 2023, and its lowest value of -$52.6 million during Q4 2024.
- Moreover, its 3-year median value for EBIAT was -$38.0 million (2024), whereas its average is -$31.5 million.
- Data for Zenas BioPharma's EBIAT shows a maximum YoY plummeted of 208.42% (in 2024) over the last 5 years.
- Zenas BioPharma's EBIAT (Quarterly) stood at -$24.6 million in 2023, then tumbled by 113.93% to -$52.6 million in 2024, then plummeted by 33.40% to -$51.5 million in 2025.
- Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.